Related Experiment Video
Updated: Jun 21, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
[Effect of preliminary medication on oxaliplatin hypersensitivity]
Junya Sato1, Kazufumi Terui, Makoto Hayakari
1Dept. of Pharmacy, Hirosaki University Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 22, 2009
Summary
Preliminary medication significantly reduced oxaliplatin hypersensitivity in advanced colorectal cancer patients. This approach proved cost-effective, improving treatment safety and quality.
Area of Science:
- Oncology
- Pharmacology
- Health Economics
Background:
- Oxaliplatin is a standard chemotherapy for advanced colorectal cancer.
- Oxaliplatin hypersensitivity is a significant adverse event impacting treatment.
- Managing hypersensitivity is crucial for patient outcomes and treatment continuity.
Purpose of the Study:
- To evaluate the effectiveness of a preliminary medication regimen in preventing oxaliplatin hypersensitivity.
- To assess the medical economics of implementing this preventive strategy.
- To determine if the preliminary medication improves the safety and cost-effectiveness of oxaliplatin therapy.
Main Methods:
- Introduction of a preliminary medication protocol including escalated steroid doses and antihistamines.
- Observation of oxaliplatin hypersensitivity incidence before and after protocol implementation.
- Analysis of treatment costs, including preliminary medication and hypersensitivity management.
Main Results:
- A notable decrease in the incidence of oxaliplatin hypersensitivity was observed post-implementation.
- The cost of managing hypersensitivity was higher than the cost of the preliminary medication.
- The preliminary medication strategy resulted in overall cost reduction for patient treatment.
Conclusions:
- The preliminary medication regimen is effective in preventing oxaliplatin hypersensitivity.
- This strategy offers significant medical economic benefits by reducing overall treatment costs.
- The approach enhances the safety, cost-effectiveness, and quality of care for advanced colorectal cancer patients receiving oxaliplatin.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:12First Pass Effect
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...